Search
CELL BANK Website

Back Back
RCB2135 : NIH:OVCAR-3  update : 2018/08/02
CommentHuman cell line derived from adenocarcinoma of ovary. TKG0602 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsBasically, there is no restriction regarding academic use.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Obinata, Masuo
Originator Hamilton T.C.
Year of deposit 2005
Original cell TKG0602
Animal human < Mammals
Genus Homo
Species sapiens
Tissue ovary, ascites meta
Case history progressive adenocarcinoma of ovary
Metastastatic ability Yes
Metastatsd tissue ascites
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0602)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.02% EDTA-PBS or 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 9
User's Publication 5


To topTop
Reference
5101  Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.  Cancer Res  1983  43(11):5379-89  PubMed ID: 6604576
5102  Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF.  Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.  Cancer Res  1984  44(11):5427-31  PubMed ID: 6488194
5103  Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, Ozols RF.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.  Cancer Res  1984  44(11):5286-90  PubMed ID: 6333272
5104  Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.  Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.  Biochem Pharmacol  1987  36(1):147-53  PubMed ID: 3801051
5105  FitzGerald DJ, Bjorn MJ, Ferris RJ, Winkelhake JL, Frankel AE, Hamilton TC, Ozols RF, Willingham MC, Pastan I.  Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.  Cancer Res  1987  47(5):1407-10  PubMed ID: 3493065
5106  Holt JA, Waggoner SE, Lee EY, Hubby MM, Hamilton TC.  Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin.  Gynecol Oncol  1987  27(3):282-93  PubMed ID: 3476351
5107  Nash JD1, Ozols RF, Smyth JF, Hamilton TC.  Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro.  Obstet Gynecol  1989  73(6):1009-16  PubMed ID: 2542854
5108  Kanemoto T1, Martin GR, Hamilton TC, Fridman R.  Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel).  Invasion Metastasis  1991  11(2):84-92  PubMed ID: 1917387
5109  Chien CH1, Wang FF, Hamilton TC.  Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells.  Mol Cell Endocrinol  1994  99(1):11-9  PubMed ID: 8187952

To topTop
User's Publication
7849  Yoshida H, Sumi T, Zhi X, Yasui T, Honda K, Ishiko O.  Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.  Anticancer Res.  2011  31:1271-7  PubMed ID: 21508375
7910  Masuishi Y, Arakawa N, Kawasaki H, Miyagi E, Hirahara F, Hirano H.  Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma.  FEBS J.  2011  278:1470-83  PubMed ID: 21348943
8169  Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, Inoue M.  Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer.  Cancer Sci.  2010  101:2171-8  PubMed ID: 20678156
9868  Ito H, Yamaguchi N, Onimaru M, Kimura S, Ohmori T, Ishikawa F, Sato J, Ito S, Inoue H.  Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.  Oncol Lett  2016  12:4720-4726  PubMed ID: 28105179
9899  Saito KI, Inoue Y, Ikegami Y, Nanbo I, Onozuka M, Sano K, Yoshida H, Sakamoto T, Tatebayashi E, Fujita KI, Sasaki Y, Kitazawa T.  Investigation of Bioequivalence Between Brand-name and Generic Irinotecan Products.  Anticancer Res.  2016  36:5957-5963  PubMed ID: 27793921



Back Back Return Top Page